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Abstract 
Anemia affects about 25% of the world’s population and causes roughly 8% of all disability 
cases. The development of an affordable point-of-care (POC) device for detecting anemia 
could be a significant for individuals in underdeveloped countries trying to manage their 
anemia. The objective of this study was to design and fabricate a 3D printed, low cost 
microfluidic mixing chip that could be used for the diagnosis of anemia.  
 
Microfluidic mixing chips use capillary flow to move fluids without the aid of external 
power. With new developments in 3D printing technology, microfluidic devices can be 
fabricated quickly and inexpensively. This study designed and demonstrated a passive 
microfluidic mixing chip that used capillary force to mix blood and a hemoglobin detecting 
assay.  
 
A 3D computational fluid dynamic simulation model of the chip design showed 96% 
efficiency when mixing two fluids. The mixing chip was fabricated using a desktop 3D 
printer in one hour for less than $0.50. Blood samples used for the clinical validation were 
provided by The University of Kansas Medical Center Biospecimen Repository. During 
clinical validation, RGB (red, green, blue) values of the hemoglobin detection assay color 
change within the chip showed consistent and repeatable results, indicating the chip design 
works efficiently as a passive mixing device. The anemia detection assay tended to 
overestimate hemoglobin levels at lower values while underestimating them in higher 
values, showing the assay needs to go through more troubleshooting. 
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Chapter 1 - Introduction 
 Point-of-Care Diagnostics 
Point-of-care (POC) diagnostic tests can be performed at any location where patent care is 
provided and do not require trained technicians or a clinical laboratory [1]. A POC test 
consists of a simple device to operate at low-cost, which shows self-addressable results and 
interpretations for disease diagnosis, such as viewing a stripe, spot colors, or screen display 
[1-9]. Each test is usually a single use, disposable device that costs significantly less than 
conventional laboratory testing. Examples of simple-to-use POC tests include pregnancy, 
blood glucose, and human immunodeficiency virus (HIV) tests.  
 
The continued development of POC diagnostics is important in healthcare due to several 
advantages POC tests have over a clinical laboratory, including in-field detection, rapid 
test results, no facility required, and reduced cost [10-16]. Patients may perform POC tests 
themselves in the home, allowing them to monitor and manage their own health conditions 
with reduced medical travel expenses and time [1, 17]. 
 
 Point-of-Care Microfluidic Device Fabrication 
Microfluidics has been a significant area in developing new POC devices. Micropumps 
and microvalves in microfluidic devices enable precision in sample control and reagent 
delivery. The three types of materials most commonly used for fabricating microfluidics 
are polydimethylsiloxane (PDMS), glass, and paper. These materials have been used over 
the years and each have their own advantages and disadvantages.  
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 PDMS 
PDMS has been one of the most used and developed polymers in the area of microfluidics 
[18]. The wide range of physical and chemical advantages PDMS offers makes it a 
desirable material to work with. The most significant advantage of PDMS is a wide variety 
of surface properties [2], which allow modification for meeting fluidic flow and assay 
requirements [19, 20]. The hydrophobic nature of PDMS allows for resistance to protein 
and diatom adsorption, which essentially resists to the buildup of molecules on the surface. 
This is an important factor when picking a material for developing microfluidic devices. 
 
The fabrication of PDMS microfluidic devices is not quick. The entire process takes about 
a day and must be done in a clean room. PDMS-based microfluidic devices are fabricated 
using a microscale molding process. The PDMS chip is designed using computer aided 
design (CAD) and then printed onto a transparency. The transparency acts as a photomask 
for contact photolithography to transfer the design onto an epoxy-based (SU-8) negative 
photoresist coated surface of the master mold, which is typically a silicon (Si) wafer. 
Removal of the unpolymerized photoresist produces a positive relief creating the master 
mold. The prepolymer of PDMS is then poured into the mold and cured in an oven at 60oC 
for one hour. The polymer layer is then peeled off and pasted onto a flat plate, which is 
either polymethylmethacrylate (PMMA) or glass [21-25].  
 
 Glass 
The use of glass in the fabrication of microfluidic devices is a costly process, requiring 
trained individuals and expensive equipment. Despite the costly fabrication process, glass 
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has many properties that are desirable in making microfluidic devices, including stability, 
optical transparency, and good metal depositions [26, 27]. A few different methods are 
available to pattern microfluidic channels into glass, including dry/wet etching, 
photolithography, and electron beam lithography. All of these methods require the use of 
a clean room [28, 29]. The patterning process involves masking the glass with a metal layer 
(e.g., gold) that is sputtered using expensive deposition machine and coated with 
photoresist. The light exposed photoresist  and metal layers are then etched away to expose 
glass for  hydrofluoric acid etching [26], which is tedious and labor-intensive work 
handling hazardous chemicals. 
 
 Paper 
Many different types of paper microfluidic diagnostic tests, such as the pregnancy test, 
have been developed and brought to market. Using paper as a microfluidic device is 
competitive in the field of diagnostic technology due to the ultra-low cost, easy fabrication, 
short test times, and compatibility with existing benchtop assays in terms of sensitivity 
[30]. Paper made from 100% cotton is more desirable for diagnostic microfluidic devices 
because it is cheaper to manufacture than paper made from wood. Most studies on paper-
based microfluidics are based on chromatography and filter paper. Important parameters 
for paper-based microfluidic devices include surface area, capillary flow, pore size 
distribution, porosity, and color [31].  
 
Wax printing is a commonly used method to produce paper microfluidic devices due to its 
low cost and simple fabrication of hydrophobic barriers. Modeling software allows the wax 
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design to be patterned and printed onto the paper. Wax devices are printed by dispensing 
melted wax as liquid droplets that solidify on the surface of the paper. After printing, the 
paper is placed on a hotplate where the wax is melted into the paper to create the 
hydrophobic channels [32, 33]. This method of fabricating paper microfluidic devices is 
great for making prototypes due to a quick fabrication time of around 5 minutes.  
 
With quick fabrication time and the ability to attach many different assays, paper 
microfluidic devices have been a popular topic of microfluidic research. The main 
disadvantage of paper microfluidic devices is that they tend to be temperature and moisture 
sensitive. Due to these sensitivities, it is hard to store and ship paper-based test devices to 
underdeveloped countries as a form of POC testing.  
 
 3D Printing 
With new developments in three-dimensional (3D) printing technology, microfluidic 
devices can be made with a single piece of equipment, without the need for multiple 
fabrication steps. Unlike glass, paper, and wax fabrication methods, which produce two-
dimensional channels, a 3D printer lays down multiple layers to create three-dimensional 
channels [34]. The printing process begins with the design and modelling of a microfluidic 
chip using CAD engineering software. The software design is uploaded into a 3D printer 
where the microfluidic device is produced. One of the most commonly used fabrication 
techniques for 3D printing is stereolithographic (SLA), [35,36]. SLA printing uses a vat of 
liquid resin and an ultraviolet light to build 3D printed parts. An ultraviolet (UV) laser 
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traces the pattern of each layer on the surface of the resin, which is then cured (solidified) 
to the previously traced pattern.  
 
Most 3D printers for microfluidic fabrication use SLA with a liquid photopolymer resin as 
the printing material. A resin is a solid or highly viscous substance that is typically 
convertible into a polymer. Many resins are synthetic but certain resins are plant derived. 
Synthetic resins for 3D printing are composed of many monomers along with a small 
amount of photoinitiater.. [37]. A typical resin mixture consists of 45-55% of a diacrylate, 
11-21% of a methacrylate, and 2-3% of a photoinitiator. Resin it is considered to be an 
irritant and slightly toxic due to the photoinitiator. Once the resin is fully cured and 
solidified, it is no longer considered an irritant or toxic and is safe to handle without the 
use of gloves. 
 
One of the major advantages of 3D SLA printing is that the resolution is now comparable 
to that of PDMS microfluidic devices, but is much faster and more cost effective [38]. 3D 
printing is considered to be a “skill-less” fabrication technique that allows rapid fabrication 
of microfluidic devices and may replace PDMS as one of the main microfluidic fabrication 
techniques in the future [39. 40]. 3D printing might allow for easier access to diagnostic 
devices for anemia in underdeveloped countries due to fast fabrications times and low 
costs. 
 
 Anemia 
Anemia is a condition where an individual has below-normal levels of hemoglobin (HgB) 
in the blood, which leads to less oxygen carrying capacity. Symptoms of anemia vary and 
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can include weakness, fatigue, and other health issues [41]. In some cases, anemia can be 
severe, long lasting, or even fatal. Anemia is frequently caused by nutrient deficiencies, 
with iron deficiency being the most common. Iron deficiency anemia (IDA) and anemia 
are often used interchangeably [42]. 
 
According to the World Health Organization (WHO), anemia affects about 25% of the 
world’s population and causes roughly 8% of all disability cases. The population mostly 
effected by anemia is pregnant women and children, who are more at risk in less developed 
countries. The risk for developing anemia in less developed countries is due to various 
factors, such as limited access to healthcare services, housing, and food security [43]. 
 
The highest prevalence of anemia in both females and males over time has the same top 
causes: iron deficiency, hookworms, sickle cell disorders, malaria, and other blood 
disorders [44-48]. Developing countries that have a high prevalence of anemia tend to also 
have higher severities of anemia due to the increased chances of contact with infectious 
agents such as hookworms and mosquitoes. Coming into contact with these infectious 
agents while having anemia can make anemia more severe. 
 
The current gold standard for anemia testing is a complete blood count (CBC), which 
includes the measurement of red blood cells, white blood cells, hemoglobin, hematocrit, 
and platelets[49]. A CBC requires the use of a hematology analyzer. The CBC test standard 
relies on having access to hospitals or clinics with trained medical professionals. In 
developing countries, quality healthcare accessibility could be burdensome for patients.  
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Hemoglobin is a protein in red blood cells that carries oxygen throughout the body and is 
important in helping red blood cells maintain their normal shape. Iron binds to hemoglobin, 
which is how hemoglobin levels are analyzed when diagnosing iron deficiency anemia. 
The healthy range for hemoglobin levels vary between sexes and ages. Hemoglobin levels 
ranges from normal to severe anemia are listed in Table 1 [50]. 
 
Current management methods for anemia vary between developing countries and 
developed countries. In developed countries, an anemic individual is usually started on iron 
supplements for a few months to see if that increases their iron/hemoglobin levels. In 
developing countries, WHO provides worldwide anemia surveillance and anemia control 
interventions [51-54]. These interventions include optimizing nutrition, adding iron 
supplements, and providing bed nets to protect individuals from catching malaria from 
mosquitos.   
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Table 1. Hemoglobin levels for determining anemia* 
Population Anemia Severity Hemoglobin Levels  
Men 
(15 years of age and above) 
Normal ≥ 13.0 
Mild 11.0 – 12.9 
Moderate 8.0 – 10.9 
Severe < 8.0 
 
Children 5-11 years  
Normal ≥ 11.5 
Mild 11.0 – 11.4 
Moderate 8.0 – 10.9 
Severe < 8.0 
 
Children 12-14 years 
Normal ≥ 12.0 
Mild 11.0 – 11.9 
Moderate 8.0 – 10.9 
Severe < 8.0 
 
Non-pregnant women  
(15 years of age and above) 
Normal ≥ 12.0 
Mild 11.0 – 11.9 
Moderate 8.0 – 10.9 
Severe < 8.0 
 
Pregnant women 
 
Normal ≥ 11.0 
Mild 10.0 – 10.9 
Moderate 7.0 – 9.9 
Severe < 7.0 
 
Men 
(15 years of age and above) 
Normal ≥ 13.0 
Mild 11.0 – 12.9 
Moderate 8.0 – 10.9 
Severe < 8.0 
* Adapted from reference 50 
   Hemoglobin Levels are in grams per deciliter (g/dL) 
 
 Point-of-Care Diagnosis and Anemia 
Currently there are two types of POC devices available on the market for self-management 
of anemia, CO-Oximeters and haemoglobinometers. CO-Oximeters use a multiple 
wavelength optical sensor to noninvasively measure hemoglobin levels [55], and allows 
for continuous monitoring of hemoglobin levels. Haemoglobinometers provide rapid 
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measurement of hemoglobin levels by using a single drop of blood, but do not provide 
continuous hemoglobin level monitoring. Despite the accuracy and portability of CO-
Oximiters and haemoglobinometers, these devices are not affordable for underdeveloped 
countries, and in some cases, the general public. A single POC device usually 
costshundreds of dollars and is not able to be used outside of blood collection clinics. The 
development of an affordable POC device for detecting anemia could bring much needed 
healthcareto individuals trying to manage their anemia in both underdeveloped and 
developed countries. 
 
 Objectives 
The objective of this study was to twofold: 1) design and fabricate a 3D printed, low cost 
microfluidic mixing chip and 2) develop an anemia diagnostic assay for use with the 
mixing chip. Combined, the mixing chip and assay would act as a proof of concept for a 
microfluidic POC diagnostic device for anemia. 
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Chapter 2 - 3D POC Device Design Theory and Principles 
In microfluidics, mixing is one of the most fundamental challenges due to the tendency of 
a fluid to exhibit laminar flow at the microscale [1]. The purpose of this chapter is to look 
at the principles behind mixing at the microscale and discuss the theoretical development 
of a microfluidic mixing chip. 
 
 Calculation Theory 
Fluid flow acts differently at the microscale compared to the macroscale. The variance in 
fluid flows depends on the differences in dominant forces. Therefore, it is important to 
investigate the flow behavior of micro channels when designing an efficient microfluidic 
device. 
 
In microfluidics, the dominant factors include laminar flow, diffusion, advection, fluidic 
resistance, surface area, and surface tension [2]. The parameters used in designing 
microfluidic chips include the fluid dynamics, gravitational force, and capillary force, 
which are determined from the Reynolds Number, Bond Number (Eötvös Number), and 
Young-Laplace Equation, respectively.  
 
The Reynolds number (Re) is the ratio of internal forces to viscous forces [3]: 
𝑅𝑒 =  
𝑖𝑛𝑡𝑒𝑟𝑡𝑖𝑎𝑙 𝑓𝑜𝑟𝑐𝑒𝑠
𝑣𝑖𝑠𝑐𝑜𝑢𝑠 𝑓𝑜𝑟𝑐𝑒𝑠
 =  
𝜌𝑉𝐿
𝜇
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Where:  
 ρ= density of the fluid 
 V= kinematic viscosity 
 L= linear dimension 
 μ= dynamic viscosity of the fluid 
 
A low Reynolds number indicates that the viscous forces are dominant, while a high 
number indicates that inertial forces play the dominant role. In addition, the Reynolds 
number indicates whether a flow is turbulent or laminar. Re<2300 is laminar flow, while 
Re>4000 is turbulent flow. In small microfluidic devices Reynolds numbers are normally 
<100. 
 
The Bond number (Bo) is the ratio between gravitational force and surface tension force 
[4]: 
𝐵𝑜 =
∆𝜌𝑔𝐿2
𝜎
 
Where: 
 ∆ρ= difference in density of the two phases 
 g= gravitational acceleration 
 L= characteristic length 
 σ= surface tension 
 
A Bond number <1 indicates that surface tension dominates, while a value >1 indicates 
gravitational forces dominate. Surface tension is the cohesion between liquid molecules 
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and the liquid/gas interface. Both Reynolds numbers and Bond numbers give good 
indications of what the driving force is in passive mixing microfluidic devices. In most 
microfluidic devices with hydraulic diameters less than 1000 microns, surface tension is 
usually dominant. 
 
Diffusion is the spontaneous movement of particles from an area of high concentration to 
an area of low concentration that does not require the use of energy. In the absence of 
turbulent flow, diffusion dominates the mixing of fluids in microfluidic devices. Diffusion 
also plays a part in mixing in laminar flows. Over time, the average concentration of 
particles throughout the channel will become constant through diffusion. Advection, the 
transfer of matter by fluid flow, enhances diffusion. Advection causes an increase in the 
interfacial area by transporting mixed fluid away from the interface and introducing new 
non-mixed fluid [5]. This phenomenon vastly increases mixing time as the rate of diffusion 
increases. At high Reynolds numbers, advection dominates fluid transport, making 
diffusion negligible. At moderate Reynolds numbers, fluid flow remains laminar and the 
internal forces become significant as fluid passes through complex channel geometries. 
Microchannels (<1000 microns) require high velocities (>100 millimeters/second [mm/s]) 
to produce adequate mixing.  
 
Capillary flow has received a lot of attention in microfluidics because it moves fluids 
without the aid of external power [6-8], therefore, it is important to understand the physics 
of capillary flow to properly design a microfluidic-mixing device. A balance between 
capillary force and viscous drag determines the flow rate of a fluid [9]. The capillary force 
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is determined by the channel geometry and the water-air surface tension. This force is 
characterized by the Young-Laplace Equation [10]: 
∆𝑃 =
4𝜎
𝐷
 
 Where: 
  ∆P= pressure drop 
  σ= surface tension 
  D= channel diameter 
 
The pressure drop (∆P) can also be expressed in the following equation: 
∆𝑃 =
64
𝑅𝑒
𝐿
𝐷
𝑉2
2
𝜌 
 Where: 
  ∆P= pressure 
  Re= Reynolds number 
  L= wetted length 
  V= flow velocity (inversely proportional to the wetted length) 
  ρ= density of fluid 
 
 Theoretical Design 
One of the main goals of the POC device design was to create a passive microfluidic mixing 
device using capillary force. Capillary force is the ability of a liquid to flow through a 
channel without the assistance of external forces. The diameter of the channel, surface 
tension, and adhesive forces between the liquid and the channel are what move liquids 
through passive microfluidic mixers that use capillary force. 
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Microfluidic devices are typically composed of different basic structures in order to 
achieve mixing. These basic structures include the T- or Y-junctions, pillars, channels, and 
cavities. Passive micromixers are able to operate and mix efficiently without the aid of a 
pump. There are many different types of passive mixers, which include distributive mixers, 
static mixers, T-type/Y-type mixers, and vortex mixers [11]. These types of micromixers 
use channel geometry to move fluid streams to increase the area of diffusion. Laminar flow 
is the dominant flow for most microfluidic devices and usually prevents mixing except 
through diffusion [12-13]. Therefore, the objective of the design process is to create a 
microfluidic device that induces diffusion to enhance mixing. 
 
A Y-type mixer, that is able to introduce blood and assay reagents at the same time, was 
selected as the basic structure for the microfluidic mixing chip. The chip inlets protrude 
out of the chip to make it easier to draw the reagents into the chip via capillary action. To 
increase the contact surface, rings were added to split the two fluid streams and recombine 
them to induce mixing. Studies have shown the effectiveness of splitting and recombining 
fluid flows to enhance diffusion [14-15]. This initial design is designated as Chip A. 
 
 Results 
 3D Microfluidic Simulation 
Using a computational simulation during the prototyping stage is an efficient way to 
identify problems or validate a design prior to fabrication. Chip A’s effective capillary-
force driven auto-mixing was evaluated using the 3D computational fluid dynamic (CFD) 
21 
simulation module in COMSOL Multiphysics®. The program has an integrated user 
interface designed for cross-disciplinary product development dealing with electrical, 
mechanical, fluid, and chemical applications. The CFD module can analyze multiple 
parameters simultaneously and is used for simulating devices and systems involving 
sophisticated fluid flow models. Add-ons make it possible to import and edit files such as 
AutoCAD® and SolidWorks® directly within the program.  
 
The Chip A design was imported into the COMSOL Multiphysics® to calculate the 
relevant parameters associated with the chip. The chip parameters calculated by the 
simulation are shown in Table 2.  
Table 2. Chip A parameters for COMSOL simulation 
Channel Diameter 1mm 
Length ~30mm 
Final Velocity 337 mm/s 
Total Flow Rate 265µL/s 
Residence Time 0.045s 
Reynolds Number (final) 379 
Bond Number 0.136 
 
The simulation showed that the Chip A design had a Bond number <1, indicating that it is 
capillary force dominant and works as a passive micromixer. The relatively short channel 
length of the design resulted in a high capillary driven flow rate of 265 microliters/second 
(µL/s). The calculated flow information was then used to provide input parameters for the 
CFD analysis. The analysis assumes the two fluids enter the Y-junction at half of the 
calculated velocity. The two-phase (liquid-liquid) CFD analysis introduced blood in one 
inlet and reagent in the other. Both fluids were assumed to have the same physical properties 
as water. The level of mixing for the chip was measured at the viewing window after the 
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flow reached steady state (not varying with time). The value was then averaged over the 
viewing port volume (~2mm in diameter). The mixing efficiency of the chip was calculated 
to be 69% mixed once the fluid flow had reached the viewing window. Figure 1 shows the 
Chip A COMSOL mixing simulation. Figure 2 shows there is incomplete mixing of 
hemoglobin powder solution and assay on the side of the rings in Chip A,  
 
 
Figure 1. Chip A mixing simulation 
 
Figure 2. Incomplete mixing hemoglobin powder solution and assay in Chip A  
 
Based on the results of the CFD simulation, the design was modified to rotate the ring 
portion of the chip 90 degrees to see if the mixing efficiency would increase. A rerun of the 
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simulation run with the modified design showed a mixing efficiency of 96% mixed once 
the fluid flow had reached the viewing window as shown in Figure 3.  
 
Figure 3. Chip B mixing simulation 
 
The rotation of the ring portion of the chip increased its total thickness, resulting in a 
decrease in the optical transparency, making the colors harder to see. Therefore, the design 
was changed to reduce the distance from window to the top of the chip to increase 
transparency. The modified design, with the ring rotation and changes to the viewing 
window, was designated as Chip B. The chip parameters from Table 2 are the exact same 
for Chip B since the design of the chip was not changed, just the orientation of the rings. 
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Chapter 3 - Methods and Materials 
Materials 
Materials used in this project include Visijet FTX clear resin from D3 technologies, and 
potassium hydroxide (KOH), ethylene glycol, 3,3',5,5'-tetramethylbenzidine (TMB), 
hydrogen peroxide (H2O2) from Sigma Aldrich. 
 
 Chip Fabrication 
A 3D representation of the microfluidic device was drawn in AutoCAD® using the polyline 
tool (Figure 4). The channels were drawn using the sweep and extrude tools (Figure 5). A 
box was then created around the channels using the box tool to create the body of the device 
(Figure 6). For the last step the subtract tool was used to remove the channels from the box, 
leaving a hole where the microchannels used to be (Figure 7). The subtract tool is what 
created the usable microchannels inside of the device. The finished product in Figure 7 is 
Chip B.  
 
After the design is finished the design is sent to the 3D printer and created. 
After the chip was printed, it went through a washing process to remove excess resin from 
of the chip and out of the channels. The chip was placed in fresh isopropyl alcohol (IPA) 
for 2 min and then transferred into a container of fresh IPA for another 2 min. After the 
washing process, the excess resin inside in the channels was blown out using nitrogen gas 
and was then fully dried. The chip was then placed in the post curing UV chamber for 30 
min, where it is allowed to fully cure. Once the chip was post cured, it was treated with a 
ethylene glycol and 10% potassium hydroxide solution for 1 hour at 55oC to make the chip 
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more hydrophilic [1]. After treatment, the chip was thoroughly rinsed with water to remove 
left over ethylene glycol solution and is then dried with nitrogen gas.  
 
 Assay Optimization 
To create the 8 g/dL solution of hemoglobin powder 3.2mg of hemoglobin powder was 
inserted into a micro centrifuge tube containing 20 µL of phosphate buffered saline 
(PBS). The tube was then vortexed to ensure adequate mixing and then placed on ice. 
The anemia diagnostic assay consisting of TMB and H2O2 was then prepared by adding 
3398 µL of TMB and 2 µL of H2O2. The TMB/H2O2 solution was placed one ice after 
preparation. To test the assay, 50 µL of the HgB solution (or blood) was diluted in 450uL 
1x PBS buffer. 50 µL of the diluted HgB solution was then added to another test tube 
along with 50 µL of the TMB/H2O2 solution. The combined solutions were then pipetted 
5 times to ensure adequate mixing. The reaction was left to sit for 1 min and after that 
time a digital photo was taken using a LGG3 smartphone. The tests were repeated using 
12 g/dL (6 mg HGB powder/ 20 µL PBS) and 16 g/dL (3.2 mg HGB powder/ 20 µL 
PBS).  
 
When the assay was tested on the mixing chip instead of the tubes 50 µL of the HgB 
solution (or blood) and TMB/H2O2 solution were pipetted onto a PDMS slide. The 
mixing chip inlets were then touched to both reagents where capillary actions draws in 
the liquids into the microchannels and mixes them. After 1 min a digital photo of the 
viewing window was taken using a LGG3 smartphone. 
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 ImageJ 
ImageJ was used to analyze the digital photos taken of the chip and tube reactions. The 
photos were saved as a .JPEG and imported into the software program. The histogram 
tool was used to analyze the RGB colors of each image and a screenshot of the data was 
taken and imported into a large spreadsheet for each patient sample for further analysis. 
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Chapter 4 - 3D Fabrication of Anemia Diagnostic Chip 
The 3D printer used to fabricate the microfluidic chips is the 3D Systems’ Projet 1200®, 
with a minimum printing resolution of 36µm. Multiple print resolution tests were 
performed to determine the smallest, working microfluidic channels. Even though the 
printer resolution is 36µm, channels smaller than 100µm did not form properly or could 
not be cleared of residue resin after printing. The total thickness of the chip needed to be 
small enough to allow for the best optical transparency, but large enough for a robust chip. 
If the chip was too thin, there was risk of blowing out the channels while clearing them 
with nitrogen gas, creating a hole within the chip. The optimal thickness between the 
channel and the top of the chip was found to be 250 µm. 
 
 Computer-Aided 3D Design 
The 3D fabrication design for Chip B was drawn in AutoCAD®. AutoCAD® is a computer 
software application for 2D and 3D computer-aided design and drafting, which is used 
across many different industries including architecture, engineering, and graphic design.  
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Figure 4. 2D representation of Chip B channels 
 
Figure 5. 3D representation of Chip B channels 
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Figure 6. Addition of Chip B outline to channels 
 
Figure 7. Side view of finished Chip B design 
 
After the design was completed, the image was exported and saved as a STereoLithography 
(.STL) file for use with simulation software and the 3D printer. The .STL file format is the 
gold standard for transferring data between CAD software and 3D printers. [1] The 
information from the file is stored in triangulated sections. The more triangles defined on 
the surface of a file the increased resolution of the printed part [2]. 
 
32 
 Chip Fabrication 
Each chip was fabricated using 3D System’s Projet 1200®. The Projet is a micro-SLA 3D 
printer that is compact and easy to use. The printer has a build volume of (43 x 27 x 150 
mm) with a resolution of 36µm. The printing speed of the Projet 1200® is up to 14mm/hour, 
which allows you to go from design to prototype in just a few hours (in my case only one 
hour). The fabrication process is quite simple and allows prototyping with ease. 
 
The chip design was uploaded into the printer software as an .STL file and manipulated by 
adding supports and changing the orientation on the print platform. Adding supports to the 
chip is necessary to allow the chip to print out properly; otherwise, the chip ends up falling 
inside of the resin tank. The orientation of the chip on the print platform is important 
because the chip prints upside-down. Due to this factor, the outlet is the last thing printed 
so that the microchannels can be cleared of uncured resin.  
 
Once the design file is sent to the printer, the file is ‘sliced’ within the printer program to 
determine the layers to be printed. The print platform is then lowered into the resin cartridge 
and the chip begins to print. A UV light within the printer flashes the design pattern on to 
the liquid resin for each layer. When the UV light hits the resin, it hardens (cures) the liquid 
into to a solid. After each layer is printed, the platform slightly raises up and the next layer 
is printed right on top. When printing, it is important that the printer be kept on a stable 
surface to avoid shaking. If the printer shakes during printing, it can cause the layers to be 
misaligned, creating unusable chips. 
  
33 
 References 
1. Dolenc A, Makela I. Slicing Procedures for Layered Manufacturing Techniques. 
Comput -Aided Des. 1994 FEB 1994;26(2):119-26. 
2. Beebe DJ, Mensing GA, Walker GM. 2002. Physics and applications of 
microfluidics in biology. Annual Review of Biomedical Engineering 4:261-286.S. 
 
  
34 
Chapter 5 - Anemia Diagnostic Assay Development 
Introduction 
An anemia diagnostic assay was developed for use with the microfluidic mixing chip. The 
goal was to create an assay able to detect differences in hemoglobin levels with a visual 
color change. The assay was made by mixing 3,5,3,’5’-Tetramethylbenzidine (TMB)  with 
hydrogen peroxide (H2O2). Benzidines are used as reagents to test for blood due to the 
peroxidatic activity of blood [1]. This reaction has been used in portable point-of-care 
photometers for anemia detection and enzyme-linked immunosorbent assay (ELISA) tests.  
 
Tetrametylbenzidine Oxidation Reaction 
The reaction between TMB, hemoglobin, and H2O2 has been well documented [1-6]. The 
system yields colored products, which changes from blue, to green, and ending at yellow 
[7]. The blue product is a one-electron oxidation product of tetramethylbenzidine, while 
the yellow product is the two-electron oxidation product (diimine). The concentration of 
the hemoglobin affects the rate of the reaction but not the concentration of the formed 
product. The relationships between these products can be seen in Figure 8. 
 
During this process, the heme center of the hemoglobin reduces peroxide to water under 
the equation: 
H2O2 + 2e
- + 2H+ = 2H2O 
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Figure 8. 3,5,3,’5’-Tetramethylbenzidine oxidation reaction 
 
The consumption of protons raises the pH of the solution. From previously published 
literature [1,2], expected color changes should include blue, green, yellow, orange and red, 
with blue color indicating severe anemia and red indicating no anemia.  
 
 Optimization Methods 
Before working with human blood, human hemoglobin powder was used to catalyze the 
reaction between TMB and H2O2 in test tubes. After reviewing multiple ELISA substrates 
containing TMB and H2O2, the recommended ratio was 1:2 or 1:3 ratio [1] of TMB/H2O2. 
The initial experiments started with a 1:3 ratio (1650µM of TMB to 4950 µM of 30% 
H2O2). The hemoglobin powder concentrations used were 8g/dL, 12g/dL, and 16g/dL to 
simulate severe anemia, mild anemia, and no anemia.  
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 Results/Discussion 
The tube reactions gave varying color changes from blue, to yellow/orange, to orange after 
1 minute, having colors ranging gave a nice visual correlation between color and 
hemoglobin counts. The observed results showed the expected color variation for the 
hemoglobin powder concentrations as shown in Figure 9. 
 
Figure 9. Hemoglobin powder assay optimization in tubes. From left to right: 16 g/dL, 12 
g/dL, 8 g/dL. 
 
The colors in the chips came out slightly different from the ones in the tubes as seen in 
Figure 10. The 8 g/dL was very similar to the tube, but the 16 g/dL turned out to be more 
of a yellow/green than a yellow/orange. Even though there were slight color differences 
between the chips and the tubes, the assay optimization established a starting point for use 
with patient samples. Figure 11 shows complete mixing of hemoglobin powder 8 grams 
per deciliter (g/dL) and 16 g/dL solution throughout Chip B. 
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Figure 10. Hemoglobin powder assay optimization in mixing chips (16 g/dL and 8 g/dL) 
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Figure 11. Complete mixing hemoglobin powder solution and assay in Chip B. (8 g/dL 
and 16 g/dL) 
 
 Blood Hemoglobin Assay Optimization 
The anemia detection assay needed to be optimized for the clinical patient blood samples. 
Initially, anemic blood samples were diluted by 10x, but the dilution was not enough to 
show the blue charge transfer complex ; the red color of the heme was too intense to show 
the blue hue. The blood samples were then diluted by 50x and 100x to see if any color 
changes were visible. The 50x and 100x dilution results can be seen in Figure 12. With 
these results, it was concluded that the samples needed to be diluted by 100x to see any 
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color change, since any dilution beyond 100x would produce no visible color change. After 
the assay was re-optimized for the patient blood samples, the point-of-care microfluidic 
device was ready for testing. 
 
Figure 12. Comparison of HgB powder, anemic patient 50x Dilution, anemic patient 100x 
assay Optimization 
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Chapter 6 - Clinical Validation 
 Laboratory Facilities 
Work with human blood poses a moderate health hazard due the potential for exposure to 
human diseases and infectious organisms. In addition to standard safety practices for 
Biosaftey Level 1 (BSL 1) laboratories, the facility must meet Biosafety Level 2 (BSL 2) 
standards. These standards include precautions to prevent injury (needle sticks, cuts, 
ingestion, and mucous membrane exposures), controlled access to the lab, and equipment 
such biosafety cabinets, personal protective equipment, autoclave, and eyewash station. 
 
To meet BSL-2 standards, a biosafety manual and standard operating procedures were 
prepared and submitted to the Kansas State University Institutional Biosafety Committee 
(IBC #1082 and IRB #8032) for review and approval.  Approval of the facility as a BSL-2 
lab was received prior to receiving and testing clinical samples. 
 
 Clinical Samples 
Blood samples with hemoglobin counts used for the clinical validation were provided by 
The University of Kansas Medical Center Biospecimen Repository. Samples were 
collected from lists healthy and anemic patients within their database, two from non-
anemic (normal) patients and 16 from anemic patients. Each sample was preserved in acid 
citrate dextrose (ACD) anticoagulant and stored at 4oC until pickup. Once the samples were 
received, they were stored at 4oC, if being used the same day, or at -80oC for later testing.  
The hemoglobin counts for the clinical samples are listed in Table 3. HgB values ranged 
from 6g/dL to 14.5g/dL. A histogram (Figure 13) of the data indicates normal distribution 
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of the data. The exact numbers of the hemoglobin values for each sample were not received 
until after the study was complete. When samples were received the possible range of the 
hemoglobin levels was known, but the exact hemoglobin levels for each sample was not 
known during the time of testing. 
Table 3. Hemoglobin counts of patient samples. 
Sample 
Number 
Patient 
Number 
HgB 
1 15267 6 
2 17669 7.3 
3 17193 7.5 
4 12218 8.3 
5 16367 8.5 
6 20258 8.6 
7 20452 8.8 
8 5996 9.5 
9 20737 9.6 
10 19262 9.7 
11 5675 9.7 
12 3659 9.8 
13 20485 10.1 
14 15429 10.1 
15 14476 10.2 
16 20247 11.7 
17 16701 14.1 
18 10439 14.5 
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Figure 13. Histogram of hemoglobin ranges of patient samples 
 
 Testing Procedures 
 Test Tubes 
Initial testing of hemoglobin levels in patient samples was performed using test tubes to 
assess the performance of the assay independent of the mixing chips. The test tubes act as 
a control to ensure proper mixing was achieved when assessing the performance of the 
assay. The protocols for running the tube samples are as follows: 
 
1. Dilute 5µL of blood in 450µL 1x PBS solution and put on ice. 
2. Add 3498µL of TMB and 2µL of 30% H2O2  and put on ice. 
3. Add 50µL of blood to the test tube. 
4. Add 50µL of TMB/H2O2 to the test tube. 
5. Pipet the mixture 5 time and let reaction sit for 3 minutes. 
6. After 3 minutes, a digital photo of the tube is taken. 
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 Mixing Chips 
The chip design used for these tests was Chip B. The anemia test was replicated (Chip 1, 
Chip 2) for each patient sample to assess the mixing efficiency of the chips as well as the 
accuracy of the assay to predict hemoglobin levels. The mixing chips were prepped for 
testing by pipetting water into the microchannels to activate hydrophilic treatment. After 
2 minutes, the water was vacuumed from the channels. Each TMB/H2O2 reaction 
mixture was made fresh and kept on ice for each test. The blood samples were kept on ice 
when not in storage. The protocols for running the chip samples are as follows: 
 
1. Dilute 5µL of blood in 450µL 1x PBS solution and put on ice. 
2. Add 3498µL of TMB and 2µL of 30% H2O2  and put on ice. 
3. Add 50µL of blood to the PDMS slide. 
4. Add 50µL of TMB/H2O2 to the PDMS slide. 
5. The mixing chip inlets are then touched to the blood and reagent droplets on the 
PDMS surface where capillary action draws the liquids into the chip for mixing. 
6. After 3 minutes, a digital photo of the mixing chip viewing window is taken . 
 
 Data Analysis 
 Color Analysis 
The digital photos taken of the Tube, Chip 1, and Chip 2 color change for each patient 
sample test were cropped to a 150 x 150 pixel square to keep the image size consistent 
during color analysis. Copies of the digital photos are provided in Appendix A. The digital 
images were analyzed using ImageJ®. ImageJ® is an open source image-processing 
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program that generates an RGB (red, green, blue) histogram along with the mean, mode, 
minimum, maximum, and standard deviation of the color spectrum. A sample of the ImageJ 
is presented below as Figure 14. The ImageJ® histograms and color data for each test is 
included in Appendix B. A summary of the ImageJ® RGB data is presented in Tables 4, 
5, and 6. 
 
 
Figure 14. Histograms from ImageJ. 
 
Table 4. ImageJ RGB values from Tube images. 
Sample 
# 
Patient # HgB R Mean G Mean B Mean 
R Std 
Dev 
G Std 
Dev 
B Std 
Dev 
1 15267 - Tube 6 163.288 155.614 134.963 4.946 4.637 4.527 
2 17669 - Tube 7.3 157.545 151.741 137.108 3.741 3.818 5.07 
3 17193 - Tube 7.5 124.197 132.221 116.941 3.841 3.024 2.989 
4 12218 - Tube 8.3 140.145 141.864 126.867 2.969 2.662 2.773 
5 16367 - Tube 8.5 127.693 132.009 112.003 3.217 2.79 3.965 
6 20258 - Tube 8.6 106.44 135.975 114.855 5.135 3.45 4.117 
7 20452 - Tube 8.8 128.733 143.034 126.299 4.539 3.975 4.394 
8 5996 - Tube 9.5 5.279 86.312 88.304 4.681 4.981 4.853 
9 20737 - Tube 9.6 138.662 141.432 125.844 3.359 3.084 3.169 
10 19262 - Tube 9.7 109.359 133.157 107.619 13.002 8.958 10.99 
11 5675 - Tube 9.7 20.154 105.503 110.278 10.259 6.246 5.557 
12 3659 - Tube 9.8 140.131 138.331 120.595 7.728 7.466 5.754 
13 20485 - Tube 10.1 118.438 127.527 115.889 8.76 6.51 6.247 
14 15429 - Tube 10.1 142.766 149 136.229 6.753 6.551 6.998 
15 14476 - Tube 10.2 132.011 125.658 107.353 4.97 4.758 5.103 
16 20247 - Tube 11.7 152.937 148.659 121.847 7.718 7.803 9.158 
17 16701 - Tube 14.1 130.046 133.682 116.31 4.789 4.181 5.446 
18 10439 - Tube 14.5 142.935 142.957 123.043 4.257 3.895 4.369 
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Table 5. ImageJ RGB values from Chip 1 images. 
Sample 
# 
Patient # HgB R Mean G Mean B Mean 
R Std 
Dev 
G Std 
Dev 
B Std 
Dev 
1 15267 - Chip 
1 
6 151.267 145.159 133.779 2.817 2.149 2.983 
2 17669 - Chip 
1 
7.3 160.663 155.989 150.34 2.75 2.624 3.433 
3 17193 - Chip 
1 
7.5 133.802 138.536 126.547 3.526 2.68 4.484 
4 12218 - Chip 
1 
8.3 147.631 148.701 141.806 3.314 3.603 4.53 
5 16367 - Chip 
1 
8.5 158.743 155.962 155.964 2.282 2.417 3.219 
6 20258 - Chip 
1 
8.6 124.617 135.408 122.46 2.639 2.155 3.323 
7 20452 - Chip 
1 
8.8 124.954 137.534 125.246 3.132 2.983 4.198 
8 5996 - Chip 1 9.5 158.618 140.855 128.835 1.924 1.901 3.001 
9 20737 - Chip1 9.6 164.378 157.202 158.9 2.355 3.624 4.956 
10 19262 - Chip1 9.7 125.029 144.854 141.295 3.677 2.83 3.553 
11 5675 - Chip 1 9.7 145.12 148.231 139.35 2.95 2.563 3.422 
12 3659 - Chip 1 9.8 155.358 144.732 133.623 2.131 1.809 2.157 
13 20485 - Chip 
1 
10.1 155.443 158.936 164.194 3.588 3.596 4.591 
14 15429 - Chip1 10.1 163.559 162.73 162.821 4.183 3.693 5.328 
15 14476 - Chip 
1 
10.2 154.554 145.251 143.921 2.209 3.177 4.586 
16 20247 - Chip 
1 
11.7 134.291 135.619 128.863 3.727 4.068 5.469 
17 16701 - Chip 
1 
14.1 150.393 133.019 131.801 2.086 3.49 3.831 
18 10439 - Chip 
1 
14.5 161.778 154.467 152.336 2.265 2.473 2.884 
 
Table 6. ImageJ RGB values from Chip 2 images. 
Sample 
# 
Patient # HgB R Mean G Mean B Mean 
R Std 
Dev 
G Std 
Dev 
B Std 
Dev 
1 15267 - Chip 
2 
6 155.489 155.489 140.169 4.665 3.422 5.909 
2 17669 - Chip 
2 
7.3 154.811 151.668 148.43 2.448 2.12 2.447 
3 17193 - Chip2 7.5 163.316 161.297 166.445 1.633 1.539 1.658 
4 12218 - Chip 
2 
8.3 149.362 149.509 149.53 3.132 3.068 3.079 
5 16367 - Chip 
2 
8.5 141.507 152.381 152.939 2.954 2.061 2.393 
6 20258 - Chip2 8.6 121.787 134.904 122.529 4.895 3.589 4.61 
7 20452 - Chip 
2 
8.8 138.761 135.087 126.614 4.437 4.383 7.808 
8 5996 - Chip 2 9.5 161.181 148.664 142.081 2.364 2.012 2.493 
9 20737- Chip2 9.6 164.306 157.264 158.938 2.614 4.126 5.609 
10 19262 - Chip 
2 
9.7 110.862 136.774 138.295 13.283 11.04 10.893 
11 5675 - Chip2 9.7 144.399 144.495 136.794 3.22 2.772 3.097 
12 3659 - Chip 2 9.8 154.942 145.025 135.948 2.77 3.284 5.53 
13 20485 - Chip 
2 
10.1 163.906 167.585 170.094 3.63 3.728 4.408 
14 15429 - Chip 
2 
10.1 164.864 162.05 162.823 2.289 2.14 2.95 
15 14476 - Chip 
2 
10.2 162.758 159.758 158.654 3.484 4.036 5.043 
16 20247 Chip 2 11.7 133.823 135.187 128.549 3.998 4.4 6.011 
17 16701 - Chip 
2 
14.1 162.646 153.345 150.455 2.452 2.58 2.895 
18 10439 - Chip 
2 
14.5 159.749 146.069 144.501 2.117 2.136 2.605 
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Column charts (Figures 15, 16, and 17) were generated to compare the RGB value means 
of Chip 1 and Chip 2 for each sample. The charts show little variance in the RGB means 
between Chip 1 and Chip 2, indicating repeatability in the mixing between the two chips.  
 
Figure 15. Column chart of Chip 1 and Chip 2 red color means. 
 
Figure 16. Column chart of Chip 1 and Chip 2 green color means. 
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Figure 17. Column chart of Chip 1 and Chip 2 blue color means. 
 
 Statistical Analysis 
 Linear Regression 
Linear regression analysis was used to model the relationship between the RGB and clinical 
HgB values. This type of analysis, also known as predictive analysis, fits the observed data 
to a linear equation. This equation can then be used to predict a value from the observed 
data. The prediction equation is: 
𝑦 =  𝛽𝑜 +  𝛽𝑥 
Where: 
 βo = intercept 
 βx = is the slope 
 
For three variables (RGB) the prediction equation is: 
𝑦 =  𝛽𝑜 + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 
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The regression analysis was performed with Microsoft Excel’s data analysis regression tool 
using the known HgB values and the measured mean RGB from Chip 1 and Chip 2 for 
each sample. Table 7 shows the intercept and slopes from the regression analysis.  
Table 7. Regression analysis coefficients. 
   Coefficients 
Intercept 27.80 
X Variable 1 (R) 0.085 
X Variable 2 (G) - 0.42 
X Variable 3 (B) 0.22 
 
The prediction equation for predicting hemoglobin levels from the RGB numbers is: 
𝑦 = 27.80 + 0.085R + (-0.48)G + 0.22B 
The known and predicted HgB levels for each sample, along with difference (residual) 
between the values, are presented in Table 8.  
Table 8. Predicted hemoglobin levels using prediction equation. 
Sample 
# 
Patient 
# 
Known 
HgB 
Chip 1 
HgB 
Chip 2 
HgB 
Tube 
HgB 
Chip 1 
Residual 
Chip 2 
Residual 
Tube 
Residual 
1 15267 6 8.4 6.6 9.1 -2.9 -0.3 -3.1 
2 17669 7.3 8.5 9.8 8.8 -1.5 -2.5 -1.5 
3 17193 7.5 8.7 10.2 9.9 -1.1 -2.9 -2.4 
4 12218 8.3 8.9 10.3 9.4 -0.6 -2.2 -1.1 
5 16367 8.5 10.1 8.8 10.3 -1.5 -0.8 -1.8 
6 20258 8.6 8.5 8.0 9.7 0.4 0.4 -1.1 
7 20452 8.8 8.3 10.7 9.2 0.8 -1.7 -0.4 
8 5996 9.5 9.4 10.6 10.2 -0.8 -0.6 -0.7 
9 20737 9.6 10.6 10.6 9.4 -1.0 -0.9 0.2 
10 19262 9.7 9.5 9.0 10.3 1.2 -0.4 -0.6 
11 5675 9.7 8.3 9.3 8.7 1.4 0.4 1.0 
12 3659 9.8 8.8 10.2 9.9 0.4 0.0 -0.1 
13 20485 10.1 10.9 8.3 9.9 -0.2 1.5 0.2 
14 15429 10.1 9.0 9.4 8.7 1.1 0.7 1.4 
15 14476 10.2 11.6 9.3 10.8 -1.3 0.9 -0.6 
16 20247 11.7 10.8 10.5 9.9 1.3 1.2 1.8 
17 16701 14.1 13.8 10.4 10.0 0.5 3.9 4.1 
18 10439 14.5 9.9 12.0 9.7 4.5 2.8 4.8 
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How well the data fits a linear relationship is determined by the regression statistics are 
summarized in Table 8. 
Table 9. Regression statistics. 
Regression Statistics 
R 0.60 
R Square 0.36 
Adjusted R Square 0.30 
Standard Error  1.75 
Observations  36 
 
Where: 
 Correlation coefficient (R) = strength the linear relationship of the data 
 Coefficient of determination (R2) = how many points fall on the regression line 
 Adjusted R Square = used when there are multiple X values 
 Standard Error (S) = average distance that the observed values fall from the 
regression line 
 
An R value of 1 shows a positive correlation between the two sets of data, while a value of 
0 shows no relationship. The R value of 0.60 indicates that there is not a strong linear 
relationship in the data. The adjusted R2 (for multiple X values) is 0.30, which means 30% 
of the data fit the model. S indicates how wrong the regression model is on average using 
the units of the response variable (in this case hemoglobin count). Smaller values are better 
because it indicates that the observations are closer to the fitted line. This number is saying 
the average distance of the data points from the plotted line is a hemoglobin count of around 
1.75. 
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The output from the linear regression was used to create a Bland and Altman Plot to show 
a visual correlation between the known and predicted hemoglobin levels.   
 
 Bland-Altman Plot 
A Bland Altman Plot is often used by researchers to compare two methods of measurement, 
or a new method of measurement with an established one, to determine whether these two 
methods can be used interchangeably or the new method can replace the established one 
[1-4]. This method calculates the mean difference (bias) between two methods of 
measurement and the limits of agreement. The limits of agreement is usually 95%, and the 
mean difference is within 1.96 standard deviations. With these plots, there is a lower limit 
of agreement and an upper limit of agreement that 95% of the data should fall within. 
 
The following parameters are used to create a Bland-Altman plot: 
 
Bias = Average of the residuals (diff between observed and predicted 
HgB) 
  Standard Deviation (Std dev) of the residuals =1.67 
  Lower Limits of Agreement = Std dev - 1.96 x Std Dev 
  Upper Limits of Agreement = Std dev + 1.96 x Std Dev 
 
The Bland-Altman plot of the data points from Chip 1 and Chip 2 is shown as Figure 18. 
This is a visual representation of how well the two methods of measurement (KUMC HgB 
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count and Chip HgB) agree with each other. The smaller range between the upper and 
lower limits of agreement, the better the agreement between the two methods.  
 
Figure 18. Bland-Altman plot showing visual correlation between known and predicted 
hemoglobin levels within 95% limits of agreement. 
 
There have been many studies done to test the precision of POC hemoglobin monitoring 
devices [5-11] compared to hospital standards. Each study stresses the importance of 
accuracy whether a test should or should not be used depending on the outcome of the 
study. Out of 32 data points, all but two of the predicted hemoglobin levels are within one 
standard deviation (95% confidence interval or +/- 3.2 limits of agreement). These statistics 
look good and meaningful but the clinical significance of the data must be considered [11]. 
In other words, does the 95% limits of agreement provide an acceptable level of accuracy 
for a diagnostic test to determining hemoglobin levels? With the range of hemoglobin 
levels being small between severe and healthy, an acceptable level of accuracy should be 
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less than 1g/dL because inaccurate readings in a clinical setting can have major health 
consequences. As shown in Figure 19, only 50% of the data are within +/- 1g/dL. 
 
Figure 19. Bland-Altman plot showing visual correlation between known and predicted 
hemoglobin levels within +/-1 g/dL. 
 
The observed vs. predicted hemoglobin levels were plotted using a column chart (see 
Figures 20 and 21) to visually represent the performance of the assay in both the chips and 
tubes. The charts show the same trends when estimating hemoglobin levels, so the assay 
performed the same in both. However, neither the chip nor the tube tests consistently 
predicted hemoglobin levels in the samples. Certain hemoglobin tests, such as the Pulse 
CO-Oximeter, have been shown to overestimate hemoglobin levels in lower values while 
underestimating them in higher values [12-13]. The same trend is evident in the chip and 
tube test data, with outliers on extreme ends of each data set. This indicates a possible 
missing element to the assay that can accurately detect high and low hemoglobin levels, 
and it is not necessarily an inconsistency based on error.  
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Figure 20. Column chart of known hemoglobin levels and predicted hemoglobin levels 
from Chip 1 and Chip 2. 
. 
 
Figure 21. Column chart of known hemoglobin levels and predicted hemoglobin levels 
from Tubes. 
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Chapter 7 - Conclusions 
The objective of this study was to twofold: 1) design and fabricate a 3D printed, low cost 
microfluidic mixing chip and 2) develop an anemia diagnostic assay for detecting anemia 
using the mixing chip. Combined, the mixing chip and assay would act as a proof of 
concept for the microfluidic chip working as a diagnostic device. 
 
Hemoglobin powder in a buffer solution and TMB/H2O2 were introduced within the chips 
to test the mixing efficiency. Chip A (initial design) did not show a uniform color change 
throughout the chip indicating incomplete mixing. Chip B, optimized using a 3D 
computational fluid dynamic simulation model, showed uniform color change throughout. 
During clinical validation, RGB values of the color change within the chip window showed 
consistent and repeatable results. Column charts of the ImageJ RGB values in replicate 
tests for each sample (Chip 1 and Chip 2) showed consistent and repeatable results. This 
indicated that the Chip B design works well as a mixing chip.  
 
Neither the chip nor the tube tests consistently predicted hemoglobin levels in the samples. 
They tended to overestimate hemoglobin levels in lower values while underestimating 
them in higher values. The over and under estimating of hemoglobin levels could be due 
to the small data set (18 patient samples). Out of 18 samples, only two were within a healthy 
range while three were within the severe range. A larger number of samples with a 
distribution across the full range of hemoglobin values (from severe to normal) would 
improve the accuracy of the regression analysis.  
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The clinical samples collected for this study were preserved with acid citrate dextrose 
(ACD). While the color change reaction between TMB and hemoglobin has been 
demonstrated in this study, the possible effect of the ACD on the TMB oxidation reaction 
and predicted hemoglobin levels was not evaluated. Future studies should test blood 
samples without preservatives to ascertain whether ACD effects the performance of the 
assay. Since blood without preservatives would be used in a POC setting, this is a logical 
next step.  
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Appendix A - Digital Images of Assay Color Change Reactions 
 
Patient HgB Tube Chip 1 Chip 2 
15267 6 
   
17669 7.3 
   
017193 7.5 
   
12218 8.3 
   
60 
16367 8.5 
   
020258 8.6 
   
020452 8.8 
   
005996 9.5 
   
20737 9.6 
   
61 
019262 9.7 
   
005675 9.7 
   
003659 9.8 
   
020485 10.1 
   
15429 10.1 
   
62 
014476 10.2 
   
20247 11.7 
   
16701 14.1 
   
 
  
63 
Appendix B - ImageJ RGB Histograms 
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Patient #17669Tubes 
   
Patient #17669 Chip 1 
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Patient #17193 Tubes 
   
Patient #17193 Chip 1 
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Patient #12218 Tubes 
   
Patient #12218 Chip 1 
   
Patient #12218 Chip 2 
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Patient #16367 Tubes 
   
Patient #16367 Chip 1 
   
Patient #16367 Chip 2 
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Patient #20258 Tubes 
   
Patient #20258 Chip 1 
   
Patient #20258 Chip 2 
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Patient #20452 Tubes 
   
Patient #20452 Chip 1 
   
Patient #20452 Chip 2 
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Patient #5996 Tubes 
   
Patient #5996 Chip 1 
   
Patient #5996 Chip 2 
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Patient #20737 Tubes 
   
Patient #20737 Chip 1 
   
Patient #20737 Chip 2 
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Patient #19262 Tubes 
   
Patient #19262 Chip 1 
   
Patient #19262 Chip 2 
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Patient #5675 Tubes 
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Patient #3659 Tubes 
   
Patient #3659 Chip 1 
   
Patient #3659Chip 2 
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Patient #20485 Tubes 
   
Patient #20485 Chip 1 
   
Patient #20485 Chip 2 
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Patient #15429 Tubes 
   
Patient #15429 Chip 1 
   
Patient #15429 Chip 2 
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Patient #14476 Tubes 
   
Patient #14476 Chip 1 
   
Patient #14476 Chip 2 
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Patient #20247 Tubes 
   
Patient #20247 Chip 1 
   
Patient #20247 Chip 2 
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Patient #16701 Tubes 
   
Patient #16701 Chip 1 
   
Patient #16701 Chip 2 
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Patient #10439 Tubes 
   
Patient #10439 Chip 1 
   
Patient #10439 Chip 2 
   
 
 
